Shanghai VisionMed Technology Co., Ltd. has successfully concluded its angel round of financing, spearheaded by the Intellectual Property Fund of the Shanghai Science and Technology Innovation Group. The proceeds will be strategically allocated towards the manufacturing of core components, certification and registration of medical devices, and the advancement of AI-assisted diagnostic and therapeutic systems. Incubated by Shanghai Jiao Tong University and founded in 2024, VisionMed is headquartered in Minhang District, Shanghai, and is dedicated to constructing a comprehensive full-chain system. The company has taken the lead in developing portable low-field cranial magnetic resonance imaging equipment and a complementary AI-assisted diagnostic and therapeutic system. These innovations boast cutting-edge key technologies and have a broad spectrum of application scenarios on a global scale. Leveraging its proprietary technology, VisionMed crafts precise diagnostic and therapeutic solutions, culminating in a full-process product matrix. The founder emphasized their commitment to intensifying R&D efforts, expediting mass production and market expansion, and delivering groundbreaking medical solutions. Investors express confidence in the growth potential of high-end medical devices, recognizing VisionMed's robust technological prowess and the alignment of its products with prevailing policy trends. They anticipate leveraging resources in the Yangtze River Delta region to further empower the company's development.